Gene Silencing with RNA Interference: A New Generation of Pharmaceuticals? - Biologics Market Research

Gene Silencing with RNA Interference: A New Generation of Pharmaceuticals?
Patent Insights, Inc.
July 20, 2006
196 Pages
Pub ID: PATI1317654
US $4,950.00 Online Download
US $7,995.00 Global Site License
Abstract
The market for RNA interference (RNAi) both as a research tool and as a new class of pharmaceuticals is projected to explode, but is the technology ready to support the expected growth? The purpose of this report is to map and assess the technology development status of RNAi and to determine which parts of the technology are ready for prime time.
Patent Insights? report provides technology maps to answer strategic questions.
Is RNAi ready for prime time?
What diseases will RNAi treat?
What technology approaches are hot or cold today?
What barriers will RNAi drugs need to overcome?
How will the technology evolve?
What companies will profit form overcoming them?
What companies will lead the way? Where are they focused?
To complete the assessment, Patent Insights identified trends in technology developments by categorizing ~12000 RNAi related patents into 82 business relevant categories. Supplementing the patent trends with information from ~13000 journal references, Patent Insights was able to assess the significance of the patent trends and to make some educated predictions about the future direction of RNAi technology.